Charles J. Dockendorff Sells 3,946 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSX) Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Boston Scientific Stock Performance

NYSE:BSX opened at $72.72 on Thursday. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The firm has a market capitalization of $106.69 billion, a price-to-earnings ratio of 61.11, a PEG ratio of 2.51 and a beta of 0.77. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The firm’s fifty day simple moving average is $68.68 and its 200 day simple moving average is $61.74.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Needham & Company LLC boosted their target price on shares of Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird lifted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Argus boosted their price target on Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James raised their price objective on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a report on Thursday, April 25th. Finally, UBS Group upped their target price on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. increased its stake in Boston Scientific by 5.6% during the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock worth $27,353,000 after buying an additional 27,620 shares during the period. Louisiana State Employees Retirement System bought a new stake in Boston Scientific in the fourth quarter valued at about $5,116,000. Glenmede Trust Co. NA lifted its holdings in Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after buying an additional 1,123 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Boston Scientific by 2.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider’s stock valued at $98,683,000 after acquiring an additional 38,249 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $3,746,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.